Bone loss prevention in cancer: New developments and perspectives

Seminars in Oncology

Volumn 37, Issue SUPPL., 2010, Pages

  Lipton, Allan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; DRUG TOLERABILITY; EDITORIAL; MEDICAL PRACTICE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; DRUG THERAPY; FEMALE; HUMANS; MALE; NEOPLASMS;

EID: 77955438768     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.06.005     Document Type: Editorial

References (7)

1. R.E. Coleman, and R.D. Rubens The clinical course of bone metastases from breast cancer Br J Cancer 55 1987 61 66
2. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 2002 584 593
3. G.D. Roodman Mechanisms of bone metastasis N Engl J Med 350 2004 1655 1664
4. M. Gnant, B. Mlineritsch, and W. Schippinger, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
5. F.C. Bidard, A. Vincent-Salomon, and S. Gomme, et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse Clin Cancer Res 14 2008 3306 3311
6. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Paper presented at: ECCO 15-34th ESMO Multidisciplinary Congress; 2009 September 20; Berlin, Germany.
7. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Paper presented at: ECCO 15-34th ESMO Multidisciplinary Congress; 2009 September 20; Berlin, Germany.